ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1893

Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses

Corinne Miceli-Richard1, Denis Poddubnyy2, Atul Deodhar3, Weibin Bao4, Craig Parman5, Brian Porter6 and Effie Pournara5, 1Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 2Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Oregon Health & Science University, Portland, OR, 4Novartis Pharmaceuticals Corporation, East Hannover, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Diagnostic criteria, Outcome measures, prognostic factors, Response Criteria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity, and the various outcome measures being mainly patient-reported, apart from radiographic progression. Using logistic regression analyses and machine learning (ML) techniques to predict the response to therapy may result in improved patient selection for optimized treatment regimens and setting the right expectations for individual patients1,2. We explored whether baseline (BL) disease characteristics could predict the response of secukinumab (SEC) therapy in AS pts, using logistic regression and ML analyses.

Methods: This post hoc analysis was performed on a pooled data of pts treated with SEC 300/150 mg from four phase 3 MEASURE studies (MEASURE 1–4)3-5 in AS (N=860). SEC 300 mg (n=113) group included 76 pts originally randomized to 300 mg and 37 pts initially randomized to placebo and then switched to 300 mg. In SEC 150 mg (n=747) group, 504 pts initially randomized to 150 mg and 243 pts initially randomized to placebo and then switched to 150 mg. A univariate logistic regression analysis was applied to search for potential BL predictors (P < 0.2) commonly collected in the MEASURE trials as demographics, disease activity parameters, prior medications etc. Various BL factors including sex, TNF status (treatment naïve vs inadequate responder), HLA-B27 status, current smoking status, concomitant NSAID use, BMI (< 30 kg/m2 vs ≥30 kg/m2), and hsCRP (elevated ≥5 mg/L vs normal < 5 mg/L) [binary variables], as well as age, MASES score, patient global assessment(PGA), and BASMI parameters [continuous variables] were assessed. Potential predictors identified in the univariate analyses were subsequently included in multivariate logistic regression models for further selection to assess their association with the response to SEC in AS pts on the following outcomes measures: ASAS40, ASDAS-Inactive Disease(ASDAS-ID), and BASDAI50. Additionally, ML Random Forest methods were applied and optimized using a grid search to find the best set of predictors.

Results: The BL factors with a significant (P < 0.05) association with the assessed outcomes of ASAS40, ASDAS-ID and BASDAI50 in multivariate logistic regression at Week 52 are presented in the Table. Age, hsCRP, occiput-to-wall distance score and MASES score were associated with ASAS40 and BASDAI50 responses. BMI, TNF status, occiput-to-wall distance score and PGA were associated with ASAS40 and ASDAS-ID responses. Additional modeling attempts using ML tree-based classification models showed similar results, without demonstrating sufficient predictive power.

Conclusion: The current analysis identified younger age, higher hsCRP, lower BMI, TNF naïve status, lower occiput-to-wall distance score and lower MASES score as factors associated with greater response that could potentially predict outcomes in AS pts treated with SEC.

References:

  1. Macfarlane, GJ et al. Rheumatology. 2020;0:1-10.
  2. Vastesaeger N, et al. Ann Rheum Dis. 2011;70:973–981.
  3. Baeten D, et al. N Engl J Med. 2015;373:2534‒48.
  4. Pavelka K, et al. Arthritis Res Ther. 2017;19:285.
  5. Kivitz A, et al. Rheumatol Ther. 2018;5:447‒62.

Table: Multivariate Logistic Regression analysis for baseline predictors of ASAS40, ASDAS-ID and BASDAI50 at Week 52: Significant Associations


Disclosure: C. Miceli-Richard, AbbVie, 2, 5, Bristol-Myers Squibb, 2, 8, Novartis, 2, 5, MSD, 2, Pfizer, 2, 5, 8, UCB, 2, 5, Biogen, 2, Wyeth, 2, 8, Schering-Plough, 8, Roche, 5, 8, Merck, 2, 5, 8, Abbott, 8; D. Poddubnyy, Eli Lilly and Company, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, BioCad, 5, Gilead, 5, GSK, 5, UCB, 5, 8, BMS, 8; A. Deodhar, AbbVie, 2, 5, Eli Lilly, 2, 5, GlaxoSmithKline, 2, 5, Novartis, 2, 5, Janssen, 5, Pfizer, 2, 5, Boehringer Ingelheim, 5, UCB Pharma, 2, 5, Amgen Inc., 5, Celgene, 5, Galapagos, 5, Bristol-Myers Squibb, 2; W. Bao, Novartis, 1, 3; C. Parman, Novartis, 3, IQVIA, 3; B. Porter, Novartis, 1, 3; E. Pournara, Novartis, 1, 3.

To cite this abstract in AMA style:

Miceli-Richard C, Poddubnyy D, Deodhar A, Bao W, Parman C, Porter B, Pournara E. Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/predictors-of-response-in-secukinumab-treated-patients-with-ankylosing-spondylitis-logistic-regression-and-machine-learning-analyses/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-response-in-secukinumab-treated-patients-with-ankylosing-spondylitis-logistic-regression-and-machine-learning-analyses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology